CMG Pharmaceutical

What CMG Pharmaceutical does

CMG Pharmaceutical (CMG Pharm Co., Ltd., KOSDAQ: 058820) is a Seoul-headquartered, publicly listed South Korean specialty pharmaceutical company founded in 1973, operating as a subsidiary of ChaBio Group. The company manufactures and sells an integrated healthcare portfolio spanning prescription drugs (cardiovascular, respiratory, gastrointestinal, endocrine, and infectious disease therapeutics), OTC medications, dietary supplements, medical devices (including the Luce ophthalmic line), pet healthcare products (via the ING MEDIX subsidiary acquired in 2023), and cosmetics (Ghrenos, Saturday Skin). Its manufacturing footprint centers on the Sihwa Factory in Gyeonggi-do, with a planned Plant No. 2 (5,863 m²) on land purchased in 2024.

The company's core differentiator is a set of proprietary drug delivery formulation platforms — Lipid Matrix, Double-Layered (Biphasic) Tablet, ODF (Orodispersible Film), and SMEDDS — plus a New Drug Discovery platform combining medicinal chemistry, in silico modeling, and PK/PD analysis. The most strategically significant application of the ODF platform is MEZOFY, an oral film-based schizophrenia treatment that received U.S. FDA marketing authorization in April 2025, marking the company's first FDA approval and its entry into regulated international markets. Past milestones include a 2021 technology export of CHC2014, a targeted anticancer drug candidate developed over 20 years.

CMG generates revenue through B2B sales to hospitals, pharmacies, and medical institutions for prescription and OTC products, and B2C sales via Naver Smart Store for supplements and pet items, supplemented by ChaBio Group's CHA Network of 96 medical centers across 7 countries. FY2025 Net Sales were KRW 105,229 million (~USD 75M), but the company reported an operating loss of KRW -3,692M and a net loss of KRW -10,077M, reflecting heavy investment in capacity expansion, M&A integration, and U.S. regulatory build-out. Pricing is not publicly disclosed; the company is led by CEO Joo Hyung Lee.

Name

CMG Pharmaceutical

Legal name

CMG Pharm Co., Ltd.

Website

https://cmgpharma.co.kr

Company type

Private

Founded year

1973

Operating status

Operating

Headcount range

101–250 employees

Short description

CMG Pharmaceutical is a South Korean, KOSDAQ-listed specialty pharma company (subsidiary of ChaBio Group) that develops, manufactures, and sells prescription drugs, OTC medications, dietary supplements, pet healthcare, medical devices, and cosmetics using proprietary drug delivery platforms, and recently received FDA approval for its MEZOFY oral film schizophrenia treatment.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Prescription pharmaceuticals
• Over-the-counter medications
• Dietary supplements
• Pet healthcare products
• Drug delivery technology

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of prescription drugs, over-the-counter medications, dietary supplements, pet healthcare products, medical devices, and cosmetics through various distribution channels.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

CMG Pharmaceutical manufactures and sells an integrated healthcare portfolio encompassing specialty prescription medications (cardiovascular, respiratory, gastrointestinal, endocrine, infectious disease), over-the-counter drugs, dietary supplements, pet healthcare products (under ING MEDIX), medical devices (eye care/Luce series), and cosmetics (Ghrenos, Saturday Skin). The company differentiates through proprietary formulation platform technologies including Lipid Matrix, Double-Layered Tablet, ODF (Orodispersible Film), and SMEDDS that improve drug delivery efficiency and patient compliance, supported by new drug discovery capabilities in medicinal chemistry and in silico research.

Product overview

CMG Pharmaceutical is building an integrated healthcare portfolio encompassing prescription and over-the-counter drugs, dietary supplements, pet healthcare (via ING MEDIX), medical devices, and cosmetics (Ghrenos brand). The company operates core platform formulation technologies including Lipid Matrix, Double-Layered Tablets, ODF (Orodispersible Film), and SMEDDS for enhanced drug delivery. The product portfolio spans multiple therapeutic areas including cardiovascular, endocrine, gastrointestinal, respiratory, and central nervous systems, supported by a New Drug Discovery division developing innovative synthetic drugs through medicinal chemistry and in silico research.

Differentiator

Problem solved

Functional benefit

Brands

• Ghrenos: Cosmetic brand including multi-collagen ampoule and prostem ampoule products for skincare.
• GHRENOS
• Saturday Skin

Products and services

• Prescription Medications Specialty pharmaceutical products covering cardiovascular, respiratory, gastrointestinal, endocrine, and infectious disease therapeutic areas, including products like Taliwon (tamsulosin) and TELO DUO (telmisartan combinations), for chronic disease management.
• Over-the-Counter (OTC) Medications Non-prescription medications available directly to consumers, including cold remedies, digestive health products, pain relief, and topical treatments.
• Dietary Supplements Health supplements including bone health products (Calcium Magnesium D, Cal-Mag-D K2 Plus), eye care (Lutein, Zeaxanthin, Astaxanthin), probiotics, omega-3 products, sleep aids (Lactium), and general wellness formulations.
• Pet Healthcare Products (ING MEDIX)

Quantifiable outcome

• CGT, mRNA, viral vector, and plasmid DNA production capability in single facility
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• ChaBio GroupcoreStrategic or Co-development Partner · 1 January 2025CMG Pharmaceutical is part of ChaBio Group, an integrated healthcare-bio innovation ecosystem connecting universities, research institutes, hospitals, and companies. This ecosystem enables efficient connection from R&D through clinical trials to commercialization.
• CGB (Cell Gene Bioplatform)coreStrategic or Co-development Partner · 1 January 2025World's largest single CGT production facility and global hub capable of producing CGT, mRNA, viral vectors, and plasmid DNA. Collaborating with domestic and international R&D centers and biotech startups as a CGT Open Innovation Hub.
• Matica BiotechnologycoreStrategic or Co-development Partner · 1 January 2025Part of Cha Biotech group in Texas, USA, focusing on immunotherapy research and cell therapy CDMO business. Leverages Cha Biotech's expertise in cell therapy manufacturing with differentiated core competencies.
• ING MEDIXcoreStrategic or Co-development Partner · 1 January 2023Animal nutrition company acquired by CMG Pharmaceutical in 2023. First in Korea to obtain HACCP certification for compound feed intended as nutritional supplements for companion animals, with thorough hygiene management from raw material selection to production.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• GC Biopharma: Korean biopharmaceutical company with a broad portfolio of vaccines, plasma-derived therapeutics, and specialty prescription drugs. Comparable to CMG Pharmaceutical through its diversified Rx portfolio and growing international footprint.
• SK Bioscience: Korean vaccine and biopharmaceutical company with global commercial ambitions and FDA experience. Comparable to CMG Pharmaceutical through its Korea-based R&D, FDA regulatory milestones, and export-driven growth strategy.
• Otsuka Pharmaceutical: Multinational pharma with strong CNS franchise (including aripiprazole, the active ingredient in MEZOFY). Comparable to CMG Pharmaceutical through its CNS drug portfolio and dominance in schizophrenia treatment — a direct competitive reference for MEZOFY's market entry.

Direct peers

• Yuhan Corporation: One of Korea's largest pharmaceutical companies with prescription drugs, OTC, supplements, and consumer health products. Comparable to CMG Pharmaceutical through its diversified healthcare portfolio and strong Korean domestic distribution.
• Dong-A ST: Korean specialty pharma focused on prescription drugs, biosimilars, and consumer health. Comparable to CMG Pharmaceutical through its specialty Rx portfolio and emphasis on differentiated formulations and drug delivery.
• Daewoong Pharmaceutical: Korean pharmaceutical manufacturer with a broad portfolio of prescription drugs, OTC, and healthcare products and active international expansion. Directly comparable to CMG Pharmaceutical's integrated Korean healthcare portfolio and R&D-driven growth model.
• Chong Kun Dang (CKD Pharmaceutical): Korean pharmaceutical company with prescription drugs, OTC, and supplements, including export-focused specialty generics. Comparable to CMG Pharmaceutical through its mid-size Korean Rx franchise and international partnership focus.
• Hanmi Pharmaceutical: Major Korean specialty pharmaceutical company with proprietary drug delivery technologies and a global commercialization focus. Comparable to CMG Pharmaceutical through its diversified Rx pipeline, emphasis on novel formulations, and ambitions to commercialize internationally — particularly in the U.S.
• Huons: Korean specialty pharma with prescription drugs, OTC, medical devices, and cosmetics. Comparable to CMG Pharmaceutical through its integrated healthcare portfolio spanning Rx, consumer health, and aesthetics, and a similar mid-cap Korean pharma profile.

Regional players

• Ahn-Gook Pharmaceutical: Korean pharmaceutical company with prescription drugs, OTC, and supplements. Comparable to CMG Pharmaceutical through its mid-scale Korean pharma operations and similar product breadth, though with a primarily domestic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CMG Pharmaceutical